160 related articles for article (PubMed ID: 31926851)
1. PD-1 Imposes Qualitative Control of Cellular Transcriptomes in Response to T Cell Activation.
Shimizu K; Sugiura D; Okazaki IM; Maruhashi T; Takegami Y; Cheng C; Ozaki S; Okazaki T
Mol Cell; 2020 Mar; 77(5):937-950.e6. PubMed ID: 31926851
[TBL] [Abstract][Full Text] [Related]
2. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
[TBL] [Abstract][Full Text] [Related]
3. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
4. Regulation of PD-1 in T cells for cancer immunotherapy.
Yu X; Gao R; Li Y; Zeng C
Eur J Pharmacol; 2020 Aug; 881():173240. PubMed ID: 32497624
[TBL] [Abstract][Full Text] [Related]
5. Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression.
Wang Y; Sun SN; Liu Q; Yu YY; Guo J; Wang K; Xing BC; Zheng QF; Campa MJ; Patz EF; Li SY; He YW
Cancer Discov; 2016 Sep; 6(9):1022-35. PubMed ID: 27297552
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoids potentiate the inhibitory capacity of programmed cell death 1 by up-regulating its expression on T cells.
Maeda N; Maruhashi T; Sugiura D; Shimizu K; Okazaki IM; Okazaki T
J Biol Chem; 2019 Dec; 294(52):19896-19906. PubMed ID: 31723031
[TBL] [Abstract][Full Text] [Related]
7. PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8
Whelan S; Ophir E; Kotturi MF; Levy O; Ganguly S; Leung L; Vaknin I; Kumar S; Dassa L; Hansen K; Bernados D; Murter B; Soni A; Taube JM; Fader AN; Wang TL; Shih IM; White M; Pardoll DM; Liang SC
Cancer Immunol Res; 2019 Feb; 7(2):257-268. PubMed ID: 30659054
[TBL] [Abstract][Full Text] [Related]
8. PD-1 preferentially inhibits the activation of low-affinity T cells.
Shimizu K; Sugiura D; Okazaki IM; Maruhashi T; Takemoto T; Okazaki T
Proc Natl Acad Sci U S A; 2021 Aug; 118(35):. PubMed ID: 34433672
[TBL] [Abstract][Full Text] [Related]
9. TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer.
Park BV; Freeman ZT; Ghasemzadeh A; Chattergoon MA; Rutebemberwa A; Steigner J; Winter ME; Huynh TV; Sebald SM; Lee SJ; Pan F; Pardoll DM; Cox AL
Cancer Discov; 2016 Dec; 6(12):1366-1381. PubMed ID: 27683557
[TBL] [Abstract][Full Text] [Related]
10. PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2.
Xu X; Hou B; Fulzele A; Masubuchi T; Zhao Y; Wu Z; Hu Y; Jiang Y; Ma Y; Wang H; Bennett EJ; Fu G; Hui E
J Cell Biol; 2020 Jun; 219(6):. PubMed ID: 32437509
[TBL] [Abstract][Full Text] [Related]
11. PD-1 Primarily Targets TCR Signal in the Inhibition of Functional T Cell Activation.
Mizuno R; Sugiura D; Shimizu K; Maruhashi T; Watada M; Okazaki IM; Okazaki T
Front Immunol; 2019; 10():630. PubMed ID: 31001256
[TBL] [Abstract][Full Text] [Related]
12. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
13. Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy.
Li Y; Cong Y; Jia M; He Q; Zhong H; Zhao Y; Li H; Yan M; You J; Liu J; Chen L; Hang H; Wang S
Nat Commun; 2021 Feb; 12(1):951. PubMed ID: 33574265
[TBL] [Abstract][Full Text] [Related]
14. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment.
Li J; Jie HB; Lei Y; Gildener-Leapman N; Trivedi S; Green T; Kane LP; Ferris RL
Cancer Res; 2015 Feb; 75(3):508-518. PubMed ID: 25480946
[TBL] [Abstract][Full Text] [Related]
15. The Inhibitory Signaling Receptor Protocadherin-18 Regulates Tumor-Infiltrating CD8
Frey AB
Cancer Immunol Res; 2017 Oct; 5(10):920-928. PubMed ID: 28874354
[TBL] [Abstract][Full Text] [Related]
16. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen J; Jiang CC; Jin L; Zhang XD
Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
[TBL] [Abstract][Full Text] [Related]
17. T cell checkpoint regulators in the heart.
Grabie N; Lichtman AH; Padera R
Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
[TBL] [Abstract][Full Text] [Related]
18. Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.
Schlenker R; Olguín-Contreras LF; Leisegang M; Schnappinger J; Disovic A; Rühland S; Nelson PJ; Leonhardt H; Harz H; Wilde S; Schendel DJ; Uckert W; Willimsky G; Noessner E
Cancer Res; 2017 Jul; 77(13):3577-3590. PubMed ID: 28533272
[TBL] [Abstract][Full Text] [Related]
19. Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.
Dong ZY; Wu SP; Liao RQ; Huang SM; Wu YL
Tumour Biol; 2016 Apr; 37(4):4251-61. PubMed ID: 26779629
[TBL] [Abstract][Full Text] [Related]
20. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY
Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
